Charalampia Kyriakou

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Shaji Kumar, Meletios Α. Dimopoulos, Efstathios Kastritis et al. · Leukemia · 2017 · 354 citations · Full text

Medicine, Immunology, Oncology +17

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

María‐Victoria Mateos, Shaji Kumar, Meletios Α. Dimopoulos et al. · Blood Cancer Journal · 2020 · 275 citations · Full text

Medicine, Hematology, Oncology +12

Allogeneic Stem Cell Transplantation Is Able to Induce Long-Term Remissions in Angioimmunoblastic T-Cell Lymphoma: A Retrospective Study From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Charalampia Kyriakou, Carmen Canals, Jürgen Finke et al. · Journal of Clinical Oncology · 2009 · 168 citations

Medicine, Hematology, Oncology +15

High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Charalampia Kyriakou, Carmen Canals, Anthony P. Goldstone et al. · Journal of Clinical Oncology · 2007 · 155 citations

Medicine, Hematology, Oncology +15

Low‐dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

Charalampia Kyriakou, Kirsty Thomson, Shirley D’Sa et al. · British Journal of Haematology · 2005 · 116 citations

Medicine, Pharmacology, Pharmacotherapy +12